Skip to content
Biodatica
Start free

AstraZeneca

Los Angeles, California

OncologyPhase IListed · AZN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: Phase I Trial of VS-6766 Alone and in Combination With Everolimus

5mo agoTrial registeredJan 29, 2026Source filing (opens the source filing in a new tab)

Momentum

64no change

Momentum 64 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Jun 17, 2013

    Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer · COMPLETED · sponsor: Royal Marsden NHS Foundation Trust · Phase I Trial of VS-6766 Alone and in Combination With Everolimus

    ClinicalTrials.gov · NCT02407509 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Dec 1, 2010

    Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive · COMPLETED · sponsor: AstraZeneca · Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

    ClinicalTrials.gov · NCT01226316 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources